The Origin of our Success Story
As Europe’s largest biopharmaceutical multi-product plant for mammalian cell culture, our Biberach site offers the development and manufacture of therapeutic proteins and antibodies in one pilot plant and two large-scale manufacturing facilities. The site began operations in 1983, marking one of the major milestones for Boehringer Ingelheim BioXcellence™.
The single-use plant that houses bioreactors from 100 L to 500 L as well as a disposable downstream processing facility provides the entire value chain from research and development to production. Fed-batch processes in large-scale bioreactors of 15,000 L are a core technology, but Biberach also offers perfusion processes in 2,000 L bioreactors established within the commercial facilities.
Tailor-made services for your success.
|History:||Boehringer Ingelheim’s first plant started in 1983 and became the largest in Europe.|
|Employees:||more than 2,600|
|Standout Characteristics:||Center of excellence for cell line development (BI-HEX® CHO-K1)|
|Technology:||Mammalian Cell Culture
Stainless Steel and Single-Use Bioreactors
Cell line and process development
Clinical and commercial
Launch site for almost all of our customers commercial mammalian products
Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
25+ years’ experience in clinical Fill & Finish
15+ years’ experience in manufacturing clinical and commercial cell banks
60 different biologics and about 80 different processes for manufacturing pre-clinical and clinical material
200 master, working and bioassay cell banks